Inclusion Criteria:

- stamp bioptic secured prostate cancer with intermediate or high risk profile (defined
as Gleason-Score 7-10 or PSA > 10 ng/ml)

- locally-operable tumor according to DRU/TRUS

- negative bone scan

- negative CT abdomen / pelvis

- general condition according to Karnofsky >/= 80%

- written consent of the patient

- adequate hematological, renal and coagulation physiological functions

- Patient compliance and geographic proximity to allow adequate follow-up

Exclusion Criteria:

- Manifest secondary malignancy

- Secured metastasis by histologically or by imaging

- Myocardial infarction or stroke within the last 6 months

- Existing major cardiovascular (grade III - IV according to NYHA), pulmonary (pO2 <60
mmHg), renal, hepatic or hematopoietic (eg severe bone marrow aplasia) diseases

- Severe active or chronic infections (eg pos. HIV-Ab test, HBs-Ag detection in serum
and / or chronic hepatitis)

- severe psychiatric disease

- prior chemotherapy (allowed is a preoperative antiandrogen therapy ≤ 3 months)

- previous pelvic radiotherapy

- Patients in a closed institution according to an authority or court decision

- People who are in a dependent relationship or working relationship with the sponsor
or investigator

- simultaneous participation in another clinical trial